Remove Biobanking Remove Genome Project Remove Medicine
article thumbnail

UK agency pilots biobank to study links between genetics and drug side effects

Pharmaceutical Technology

The Medicines and Healthcare products Regulatory Agency (MHRA) aims to launch a pilot genetic biobank that will gather patient data to associate drug-related adverse events to their genetic makeup. The Yellow Card biobank will launch as a joint venture with the UK-government funded entity Genomics England on June 1.

article thumbnail

A new dawn of the genomic age: five areas set to be transformed in 2023

pharmaphorum

A 2022 study from the Royal College of Physicians and British Pharmacological Society demonstrated the potential of pharmacogenomics, with scientists identifying the genetic cause behind an individual’s drug response for over forty medicines.

Genome 130
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Can genetic data be a magic bullet for drug R&D?

pharmaphorum

The same is becoming true for the healthcare industry, and one of the first major breakthroughs in the area was the 100,000 Genomes Project. The information gathered from the project is still providing insights today, a decade later. Certain genetic variants influence the way the body responds to specific medicine.

article thumbnail

Boehringer Ingelheim and Lifebit announce partnership to capture transformational value of health data

The Pharma Data

to build a scalable data, analytics, and infrastructure platform This collaboration aims at capturing translational disease insights from large external healthcare biobanks and maximizing value of data for drug discovery and precision medicine. Boehringer Ingelheim partners with Lifebit Biotech, Ltd.